In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 54 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.

Effects of low blood pressure on cardiovascular events in diabetic patients with coronary artery disease after revascularization - The CREDO-Kyoto cohort-1

Session Hypertension - Epidemiological and diagnostic aspects

Speaker Hisashi Kai

Event : ESC Congress 2018

  • Topic : hypertension
  • Sub-topic : Hypertension - Clinical
  • Session type : Rapid Fire Abstracts

Authors : H Kai (Kurume,JP), H Niiyama (Kurume,JP), Y Rikitake-Iwamoto (Kurume,JP), H Harada (Kurume,JP), A Katoh (Kurume,JP), Y Furukawa (Kobe,JP), T Kimura (Kyoto,JP)

Authors:
H. Kai1 , H. Niiyama1 , Y. Rikitake-Iwamoto1 , H. Harada1 , A. Katoh1 , Y. Furukawa2 , T. Kimura3 , 1Kurume University Medical Center, Cardiology - Kurume - Japan , 2Kobe City Medical Center General Hospital, Division of Cardiology - Kobe - Japan , 3Kyoto University Graduate School of Medicine, Department of Cardiovascular Medicine - Kyoto - Japan ,

On behalf: CREDO-Kyoto Cohort-1 Investigators

Citation:
European Heart Journal ( 2018 ) 39 ( Supplement ), 634

Background: The new 2017 ACC/AHA high blood pressure (BP) guidelines lowered the target BP for patients with diabetes mellitus (DM) to 130/80mmHg or less. However, there is a concern that extremely low BP may increase cardiovascular (CV) events in DM patients, especially in DM patients with coronary artery disease (CAD). Coronary revascularization has become prevalent in diabetic CAD patients.

Purpose: We investigated the effects of low SBP and DBP on CV events in diabetic CAD patients after coronary revascularization.

Methods: We examined 2,718 DM patients with stable, chronic CAD registered in the CREDO-Kyoto cohort-1, a prospective multi-center registry, enrolling 9,877 CAD patients who underwent the first CABG or PCI.

Results: CV death was not affected by low SBP, whereas DBP below 70 mmHg slightly but not significantly increase CV death (Figure). Low SBP and DBP did not change the risk of non-fatal myocardial infarction and non-fatal stroke. On multivariate Cox proportional hazard regression analysis, DBP below 70 mmHg was not a significant factor for increasing CV death, while creatinine clearance (hazard ratio [HR] 0.970 [95% confidence interval; 0.961–0.978], p=0.000), statin use (HR 0.428 [0.227–0.844], P=0.014), pulse pressure (HR 1.016 [1.003–1.030], P=0.015), hypertension (HR 2.420 [1.090–5.373], P=0.030), and prior myocardial infarction (HR 1.804 [1.037–3.139], P=0.037) were the independent factors for CV death.

Conclusions: In diabetic CAD patients after coronary revascularization, low BP is not a significant factor for increasing CV events. Along with the management of risk factors and comorbidities, strict BP control targeting less than 130/80 mmHg is important for improving the prognosis of diabetic CAD patients after revascularization.



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are